Trials / Unknown
UnknownNCT02403362
Safety & Efficacy of EPO-018B for the Treatment of Anemia in Participants With Chronic Kidney Diseases Not on Dialysis
A Phase 2, Open-Label, Multi-Center , Dose-Ranging Study of the Safety and Efficacy of Pegol-Sihematide (EPO-018B) for the Treatment of Anemia in Patients With Chronic Kidney Disease Not Requiring Dialysis.
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety,efficacy， pharmacodynamics (PD), and pharmacokinetics (PK) of multiple intravenous doses of EPO-018B in participants with chronic kidney disease (CKD) Who are not on dialysis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EPO-018B |
Timeline
- Start date
- 2014-06-01
- Primary completion
- 2015-10-01
- Completion
- 2015-10-01
- First posted
- 2015-03-31
- Last updated
- 2015-03-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02403362. Inclusion in this directory is not an endorsement.